JP6560200B2 - 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 - Google Patents

自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 Download PDF

Info

Publication number
JP6560200B2
JP6560200B2 JP2016523296A JP2016523296A JP6560200B2 JP 6560200 B2 JP6560200 B2 JP 6560200B2 JP 2016523296 A JP2016523296 A JP 2016523296A JP 2016523296 A JP2016523296 A JP 2016523296A JP 6560200 B2 JP6560200 B2 JP 6560200B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
cells
composition according
bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016523296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540195A (ja
JP2016540195A5 (enExample
Inventor
ファウストマン，デニス，エル．
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2016540195A publication Critical patent/JP2016540195A/ja
Publication of JP2016540195A5 publication Critical patent/JP2016540195A5/ja
Priority to JP2019132484A priority Critical patent/JP6964632B2/ja
Application granted granted Critical
Publication of JP6560200B2 publication Critical patent/JP6560200B2/ja
Priority to JP2021170871A priority patent/JP2022023882A/ja
Priority to JP2023171996A priority patent/JP2024001123A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2016523296A 2013-10-17 2014-10-16 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 Active JP6560200B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2019132484A JP6964632B2 (ja) 2013-10-17 2019-07-18 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2021170871A JP2022023882A (ja) 2013-10-17 2021-10-19 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2023171996A JP2024001123A (ja) 2013-10-17 2023-10-03 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892140P 2013-10-17 2013-10-17
US61/892,140 2013-10-17
PCT/US2014/060908 WO2015057968A2 (en) 2013-10-17 2014-10-16 Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132484A Division JP6964632B2 (ja) 2013-10-17 2019-07-18 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物

Publications (3)

Publication Number Publication Date
JP2016540195A JP2016540195A (ja) 2016-12-22
JP2016540195A5 JP2016540195A5 (enExample) 2017-11-24
JP6560200B2 true JP6560200B2 (ja) 2019-08-14

Family

ID=52828855

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016523296A Active JP6560200B2 (ja) 2013-10-17 2014-10-16 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2019132484A Active JP6964632B2 (ja) 2013-10-17 2019-07-18 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2021170871A Pending JP2022023882A (ja) 2013-10-17 2021-10-19 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2023171996A Pending JP2024001123A (ja) 2013-10-17 2023-10-03 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019132484A Active JP6964632B2 (ja) 2013-10-17 2019-07-18 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2021170871A Pending JP2022023882A (ja) 2013-10-17 2021-10-19 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
JP2023171996A Pending JP2024001123A (ja) 2013-10-17 2023-10-03 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物

Country Status (5)

Country Link
US (2) US12174188B2 (enExample)
JP (4) JP6560200B2 (enExample)
KR (1) KR102393711B1 (enExample)
CN (3) CN111239415B (enExample)
WO (1) WO2015057968A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928035C (en) 2012-12-27 2024-07-02 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
KR102393711B1 (ko) 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
JP7085485B2 (ja) * 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
JP7171572B2 (ja) * 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
US11077179B2 (en) * 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
CN109055523A (zh) * 2018-07-16 2018-12-21 中山大学附属第三医院（中山大学肝脏病医院） Tnfr2基因及其编码蛋白的应用
KR102282342B1 (ko) * 2018-11-20 2021-07-27 아주대학교산학협력단 베체트병 진단 또는 예후 예측용 바이오마커 조성물
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
CN110804643B (zh) * 2019-10-29 2022-06-21 同济大学 一种体外评价卡介苗对中性粒细胞活性影响的方法
CN112806322B (zh) * 2021-03-22 2022-08-16 石河子大学 一种构建色素脱失模型的方法

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
SE8204382L (sv) 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0313104A3 (en) 1984-12-21 1989-07-12 Biogen, Inc. Purification, production and use of tumor necrosis factors
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4985241A (en) 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5370870A (en) 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5166142A (en) 1991-06-10 1992-11-24 University Of Rochester Use of type ia antiarrhythmic agents to lower blood lipids
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1298203A3 (en) 1991-08-02 2004-01-21 FAUSTMAN, Denise L. Diagnosis and treatment of autoimmune diseases
US6984380B1 (en) 1991-08-02 2006-01-10 Denise L. Faustman Treatment of diseases involving faulty MHC class I antigen complex presentation
US5139481A (en) 1991-08-07 1992-08-18 The General Hospital Corporation Treatment for type II diabetes
US5843425A (en) 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
EP1127577A3 (en) 1992-04-23 2002-11-27 Sloan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
DE69423806T2 (de) 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
CN1157621A (zh) * 1994-07-08 1997-08-20 达特茅斯大学理事会 用于检测和治疗i型糖尿病的胰岛素原肽化合物
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
AU7010996A (en) 1995-08-30 1997-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Selective elimination of t cells that recognize specific preselected targets
US6110206A (en) 1995-09-15 2000-08-29 Crosscart, Inc. Anterior cruciate ligament xenografts
US5874306A (en) 1996-12-12 1999-02-23 The Regents Of The University Of California Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
US5837467A (en) * 1997-01-21 1998-11-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for predicting the response to treatment with BCG of superficial bladder carcinoma
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6165737A (en) 1998-04-16 2000-12-26 The University Of Texas System Board Of Regents DNA fragmentation factor involved in apoptosis
CA2324995A1 (en) 1998-04-17 1999-10-28 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1077723A1 (en) 1998-05-18 2001-02-28 Applied Research Systems ARS Holding N.V. Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1257282A4 (en) 1999-12-06 2003-05-02 Gen Hospital Corp PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION
US6414218B1 (en) 2000-01-18 2002-07-02 The General Hospital Corporation Mouse model for rheumatoid arthritis
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
JPWO2003014336A1 (ja) 2001-08-07 2004-11-25 麒麟麦酒株式会社 造血幹細胞の製造法
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
US20040229785A1 (en) 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
CN1448724A (zh) * 2003-05-13 2003-10-15 上海晶泰生物技术有限公司 1型糖尿病相关抗原抗体同时检测蛋白芯片
EP1687411B1 (en) 2003-09-26 2015-05-06 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
EP1678317A2 (en) 2003-10-17 2006-07-12 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
EP1733733A1 (en) 2004-03-04 2006-12-20 Takashi Kadowaki Regulator for adiponectin receptor expression
US8563308B2 (en) 2004-03-10 2013-10-22 The Rockefeller University Culture-expanded T suppressor cells and methods of use thereof
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
AU2005259864A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
WO2006006165A2 (en) 2004-07-12 2006-01-19 Yeda Research And Development Co. Ltd. Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders
AU2005274852B2 (en) 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
US20080102054A1 (en) 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
CA2605253C (en) 2005-04-11 2017-06-13 Yale University Selective modulation of tumour necrosis factor receptors in therapy
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US7867765B2 (en) 2005-12-28 2011-01-11 The General Hospital Corporation Blood cell sorting methods and systems
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
JP2009014626A (ja) * 2007-07-06 2009-01-22 Medibic:Kk Ｂｃｇによる治療効果の予測方法
WO2009098682A2 (en) 2008-02-04 2009-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for treatment of mitochondrial disorders
US20090257982A1 (en) 2008-04-11 2009-10-15 Scheiber Lane Bernard medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells
EP2306959A2 (en) 2008-07-11 2011-04-13 The General Hospital Corporation Magnetic apparatus for blood separation
CA2738660A1 (en) * 2008-09-30 2010-04-08 Baylor Research Institute Methods to reduce b-helper t cells to treat autoimmune diseases
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP2192197A1 (en) * 2008-11-27 2010-06-02 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist
US20100151062A1 (en) 2008-12-16 2010-06-17 Bruno Stefanon Determining nutrients for animals through gene expression
EP2419121B1 (en) 2009-04-17 2018-07-18 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
EA201101568A1 (ru) 2009-04-28 2012-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EP2451969A2 (en) * 2009-07-07 2012-05-16 University Of Southern California Biomarkers for the early detection of autoimmune diseases
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
CA2794483C (en) * 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2011127299A1 (en) * 2010-04-09 2011-10-13 The General Hospital Corporation Methods for the treatment of autoimmune diseases
WO2011163566A2 (en) 2010-06-25 2011-12-29 Tolerx, Inc. Methods of treating patients with immune-related diseases
AU2011291651B2 (en) 2010-08-18 2016-01-14 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP2012108112A (ja) 2010-10-27 2012-06-07 Arkray Inc ＨｂＡ１ｃ測定結果の表示方法、表示装置、及び表示プログラム
WO2012122464A1 (en) 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
US9763980B2 (en) 2011-06-16 2017-09-19 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment
US9834755B2 (en) 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2820157B1 (en) 2012-03-02 2019-05-01 Winthrop-University Hospital Method for using probe based pcr detection to measure the levels of circulating demethylated beta cell derived dna as a measure of beta cell loss in diabetes
JP5900044B2 (ja) * 2012-03-12 2016-04-06 オムロンヘルスケア株式会社 糖尿病治療支援装置、糖尿病治療支援方法、糖尿病治療支援プログラム
US8969015B2 (en) 2012-11-09 2015-03-03 The General Hospital Corporation Methods and kits for diagnosing Sjögren's syndrome
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
MX391220B (es) 2013-05-14 2025-03-21 Metabolon Inc Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
KR102393711B1 (ko) * 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy

Also Published As

Publication number Publication date
CN111879948A (zh) 2020-11-03
US20160245808A1 (en) 2016-08-25
JP2022023882A (ja) 2022-02-08
KR102393711B1 (ko) 2022-05-04
CN111239415A (zh) 2020-06-05
WO2015057968A2 (en) 2015-04-23
CN111239415B (zh) 2024-03-26
CN105829885B (zh) 2020-08-18
WO2015057968A3 (en) 2015-06-11
US12174188B2 (en) 2024-12-24
JP2016540195A (ja) 2016-12-22
JP2024001123A (ja) 2024-01-09
US20250110122A1 (en) 2025-04-03
CN105829885A (zh) 2016-08-03
JP6964632B2 (ja) 2021-11-10
JP2019215354A (ja) 2019-12-19
KR20160065934A (ko) 2016-06-09

Similar Documents

Publication Publication Date Title
JP6964632B2 (ja) 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
Seibold et al. Dermal mast cell degranulation in systemic sclerosis
CN105307725B (zh) 治疗自身免疫疾病的方法和组合物
Mondino et al. Autoimmune phenomena of the external eye
Amer et al. Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease
JP2022106755A (ja) 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
US9783600B2 (en) Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
O'Donohoe et al. The role of anti-myosin antibodies in perpetuating cardiac damage following myocardial infarction
US20250304671A1 (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
HK40028012B (zh) 鉴定响应於用於自身免疫性疾病的治疗的受试者的方法以及用於治疗该疾病的组合物
HK40028012A (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
HK40036872A (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
Perrot et al. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03
Zhao et al. Pharmacokinetics, pharmacodynamics and preliminary observations for clinical activity and safety of multiple doses of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in Chinese patients with systemic lupus erythematosus
HK1227487B (zh) 鉴定响应於用於自身免疫性疾病的治疗的受试者的方法以及用於治疗该疾病的组合物
HK1227487A1 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
Grattan Histamine-releasing autoantibodies in chronic urticaria
Yin et al. Immune checkpoint inhibitor‐related myocarditis in thymic epithelial tumors: Recent progress and perspectives
Homburger et al. Diagnosis of allergy: in vitro testing
KR102895422B1 (ko) 세포성 및 체액성 면역을 도출하기 위한 인간 중간엽 줄기 세포의 사용 방법
CA3226181A1 (en) Treatment of aging frailty comprising administering bone marriw derived mesenchymal stem cells
Borrione et al. Impact of different concentrations of human recombinant growth hormone on T lymphocytes
Lopez et al. 3189 Portal Vein Thrombosis Without Cirrhosis: A Case Report
AU2005282218B2 (en) Therapeutic strategy for treating autoimmune and degenerative diseases
NZ794292A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190718

R150 Certificate of patent or registration of utility model

Ref document number: 6560200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250